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 Purpose: To directly compare parents’ perspectives of the quality of life of their 
children with Spinal Muscular Atrophy (SMA) who received supportive care, nusinersen 
(Spinraza®), onasemnogene abeparvovec-xioi (Zolgensma®), or both nusinersen and 
onasemnogene abeparvovec-xioi. Methods: The parents of children with SMA were 
recruited to complete anonymous online surveys. All surveys included qualitative 
questions about quality of life. Surveys regarding children in the 1-12-month and 13-24-
month age groups included the Pediatric Quality of Life Infant Scales assessment. 
Surveys regarding children in the 2-4-year age group included the Pediatric Quality of 
Life Inventory 4.0 Generic Core Scales and the Pediatric Quality of Life 3.0 
Neuromuscular Module assessments. The >4-year age group did not include a 
quantitative quality of life assessment. Results: The 1-12-month age group average 
physical quality of life summary score was increased for children treated with a 
combination of both nusinersen and onasemnogene abeparvovec-xioi and also those 
treated with onasemnogene abeparvovec-xioi only. The 1-12-month- age group average 
psychosocial quality of life summary score was increased for children treated with 
nusinersen only. Physical and psychosocial quality of life data regarding the 13-24-month 
age group was not statistically significant. All surveys regarding the 2-4-year age group 
and one survey from the >4-year age group were excluded to eliminate the possibility of 
identifying participants. Conclusion: It was not possible to identify and associate a single 
treatment with conferring a statistically higher quality of life; however, the quantitative 
vi 
and qualitative responses collected allowed for an inference that parents believe their 
children with SMA have a greater quality of life when provided treatment over having 
only supportive care. Before the FDA approval of the available treatments, healthcare 
providers who shared the diagnosis of SMA with parents had to also share that there was 
no known effective treatment. However, today when families hear the diagnosis of SMA, 
they can be hopeful for their child and family’s future because of the treatments available 
and the proven increase in quality of life with these treatments. Knowing how quality of 
life perspectives differ based on the type of treatment received can help in the education 
of parents of children with SMA. 
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Spinal Muscular Atrophy 
Spinal Muscular Atrophy (SMA) is the leading genetic cause of mortality in 
infants with an incidence of approximately one in every eleven thousand livebirths (Kolb 
et al., 2017; Vaidya & Boes, 2018). SMA is an autosomal recessive disease characterized 
by alpha motor neuron degeneration in the anterior horn of the spinal cord, skeletal 
muscle atrophy, and generalized weakness involving the limbs, bulbar and respiratory 
muscles (Chiriboga et al., 2016; Wirth, Karakaya, Kye, & Mendoza-Ferreira, 2020). 
There are five types of SMA that can be historically classified based on age of 
symptom onset and achieved motor abilities (Rao, Kapp, & Schroth, 2018; Vaidya & 
Boes, 2018; Wirth et al., 2020). SMA type zero is the most severe and is characterized by 
symptom onset in utero and death soon after birth. SMA type I, also known as Werdnig-
Hoffman disease, is the most common type with symptom onset before six months of age 
and without substantial treatment, a two-year life expectancy. Individuals with SMA type 
I typically have severe hypotonia, difficulty breathing, poor suck, and are unable to sit 
independently (Lunn & Wang, 2008). Individuals with SMA type II typically have onset 
of symptoms between six to eighteen months of age. They are able to sit without support, 
although they may not retain this skill, and they are not able to walk, have generalized 
muscle weakness, and many develop kyphoscoliosis (Lunn & Wang, 2008). SMA type 
III, also known as Kugelberg-Welander disease, is characterized by the onset of 
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symptoms after eighteen months of age. Individuals with SMA type III may be able to sit 
and walk independently, although they may not retain these skills, and many develop 
scoliosis (Lunn & Wang, 2008). Individuals with SMA type IV have onset of symptoms 
in adulthood and typically have mild motor impairment and respiratory problems (Lunn 
& Wang). 
Genetic Basis of SMA 
SMA is caused by homozygous loss of function mutations in the survival motor 
neuron one (SMN1) gene that encodes the survival motor neuron (SMN) protein (Finkel 
at al., 2016). The function of the SMN protein is not completely understood; however, its 
primary role is thought to be in snRNP biogenesis and splicing (Wirth et al., 2020). A 
similar gene, survival motor neuron two (SMN2), has a coding sequence identical to that 
of the SMN1 gene, except for five nucleotides (Wirth et al, 2020). Specifically, a C to T 
substitution within exon seven of SMN2 (c.840C>T) causes this exon to be spliced out of 
SMN2 mRNA transcripts 90% of the time, resulting in an unstable SMN protein that is 
rapidly degraded instead of the full-length SMN protein. It is estimated that a full-length 
SMN protein results from SMN2 approximately 10% of the time as about 10% of SMN2 
mRNA transcripts include exon seven (Helmken et al., 2003; Lefebvre et al., 1995). The 
number of copies of SMN2 generally explains the phenotypic variability between the 
different types of SMA. Approximately 80% of type I individuals have one or two SMN2 
copies, 82% of type II individuals have three copies, and about 50%-61% of individuals 
with type III and 75% of individuals with type IV have four copies (Calucho et al., 2018; 
Feldkötter, Schwarzer, Wirth, Weinker, & Wirth, 2002; Wirth et al., 2006). The more 
copies of SMN2 an individual has, the more SMN protein they produce. Those with a 
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small amount of full-length SMN protein typically have more severe symptoms, and 
those with more full-length SMN protein typically have less severe symptoms (Chiriboga 
et al., 2016; Feldkötter et al., 2002; Finkel et al., 2016; Mailman et al., 2002; Wirth et al., 
2006). 
Medical Management for Individuals with SMA 
Treatment with Nusinersen 
On December 23, 2016 the Food and Drug Administration (FDA) approved 
nusinersen (Spinraza®) as the first treatment for individuals with all types of SMA (Hoy, 
2017). Nusinersen is an antisense oligonucleotide delivered through repeated intrathecal 
injections (Finkel et al., 2016). Treatment with nusinersen includes three 12mg loading 
doses given fourteen days apart with a fourth 12mg dose given thirty days after the third 
loading dose. Continued treatment with nusinersen includes an additional 12mg dose 
every four months for life (Hoy, 2017). Nusinersen functions by altering the splicing of 
SMN2 to promote the inclusion of exon seven in SMN2 mRNA transcripts, thereby 
increasing the amount of full-length SMN protein produced (Kolb et al., 2017). 
Treatment with nusinersen costs approximately $400,000-500,000 in the first year and 
$250,000-300,000 per year thereafter for the duration of the treated individual’s lifetime 
(Wirth et al., 2020). 
In a randomized, double-blind clinical trial (ENDEAR), 122 infants with SMA 
type I aged 210 days or younger with two SMN2 copies were treated with 12mg 
nusinersen or a sham-procedure. Those treated with nusinersen had a lower risk of death 
and were more likely to reach a motor milestone (i.e., head control, ability to roll, sitting 
without assistance, and standing) than those who received the sham-procedure. Adverse 
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reactions reported (i.e., constipation, lower and upper respiratory tract infections) were 
present for both the group treated with nusinersen and the group given the sham-
procedure (Finkel et al., 2017). From this data it was concluded that early treatment with 
nusinersen may be necessary to maximize response outcomes. In a separate randomized, 
double-blind clinical trial (CHERISH), 12mg nusinersen or a sham-procedure was given 
to 126 children with SMA types II and III with onset of symptoms after six months of 
age. In this study, children treated with nusinersen showed definite motor improvement 
and higher probability of survival than the children given the sham-procedure (Mercuri et 
al, 2018a). Individuals who participated in ENDEAR and CHERISH clinical trials were 
enrolled in an open-label phase III clinical trial designed to evaluate the long-term safety 
and tolerability of 12mg of nusinersen (SHINE). An interim evaluation of SHINE data 
showed that treatment with nusinersen is safe and well tolerated (Maharshi & Hasan, 
2017; Wirth et al., 2020). 
In an open-label clinical trial (NURTURE), 25 infants six weeks or younger with 
genetically diagnosed presymptomatic SMA and two or three SMN2 copies were treated 
with 12mg nusinersen. All of these infants were living, and none needed respiratory 
intervention after day 64 of treatment. Infants from this trial who were treated with 
nusinersen but then passed away were found on autopsy to have increased SMN2 mRNA 
exon seven inclusion and increased SMN protein in the spinal cord compared to 
individuals with SMA who did not receive nusinersen (De Vivo et al, 2019; Finkel et al., 
2016). Published interim efficacy and safety outcomes from this clinical trial showed that 
the infants (now children) treated with nusinersen were living past the age of expected 
symptom onset. Additionally, 100% could sit without support, 92% could walk without 
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assistance, and 88% could walk independently. From this data it was concluded that 
treatment with nusinersen as soon as possible after a genetic diagnosis of SMA is 
established is of extreme importance (De Vivo et al., 2019). 
Treatment with Onasemnogene abeparvovec-xioi  
On May 24, 2019 the FDA approved onasemnogene abeparvovec-xioi 
(Zolgensma®) as a second treatment for patients with SMA type I under two years of age 
(Hoy, 2019). It consists of adeno-associated virus nine, which is modified to include a 
functional copy of the SMN1 gene (Hoy, 2019). Introducing a functional copy of the 
SMN1 gene into an affected person’s motor neuron cells addresses the genetic cause of 
SMA and increases the amount of SMN protein present in the body (Mendell et al., 
2017). The dosing of onasemnogene abeparvovec-xioi is 1.1 × 1014 vector genomes/kg 
body weight administered over 60 minutes as a single intravenous infusion. Treatment 
with a single injection of onasemnogene abeparvovec-xioi costs two million US dollars 
(Wirth et al., 2020). 
Fifteen infants with confirmed SMA type I and two copies of SMN2 under the age 
of six months were enrolled in a phase I open-label clinical trial (START) where 12 
infants were treated with a high dose of onasemnogene abeparvovec-xioi (2.0 x 1014 
vector genomes/kg body weight) and three infants were treated with a lower dose (6.7 x 
1013 vector genomes/kg body weight). Compared to historical cohorts of untreated infants 
with SMA, infants in this study treated with onasemnogene abeparvovec-xioi showed 
improved motor function and improved achievement of motor milestones such as sitting 
without support, rolling over, feeding orally, speaking, and walking independently. 
Additionally, it was shown that infants who received the higher dose of onasemnogene 
 
6 
abeparvovec-xioi before three months of age had improved motor function and improved 
motor milestone achievement earlier than those who also received the higher dose, but 
not until they were three months of age or older. A side effect observed was that infants’ 
liver transaminase levels were increased significantly, a finding which was hypothesized 
to be a consequence of a massive immune response against viral peptides; however, this 
was successfully controlled by daily glucocorticoid administration for one-month post 
treatment (Mendell et al., 2017). At 24 months follow-up, infants in this study showed a 
reduced amount of pulmonary interventions, stable or improved swallow function, 
sustainment of achieved motor function and milestones, and decreased hospitalization 
rate compared to historical cohorts. It was suggested that the reduction in healthcare 
utilization observed with onasemnogene abeparvovec-xioi treatment might alleviate 
patient and caregiver burden and could be associated with an improved quality of life 
(Al-Zaidy et al., 2019; Shell et al., 2019; Mendell et al., 2019). The long-term follow-up 
START results are supported by the open-label phase III clinical trial (STR1VE) where 
22 infants under the age of six months with SMA type I and one or two copies of SMN2 
were treated with onasemnogene abeparvovec-xioi and found to have rapid 
improvements in motor function that suggested future improvements in achievement of 
motor milestones and survival (Shell et al., 2019).  
In an open-label phase I dose-escalation clinical trial (STRONG), individuals with 
SMA type II and three copies of SMN2 were treated with onasemnogene abeparvovec-
xioi. In total, three patients aged >6 to <24 months were treated with 6.0 X 10^13 vector 
genomes/kg body weight onasemnogene abeparvovec-xioi and thirteen patients aged >6 
to <24 months were treated with 1.2 X 10^14 vector genomes/kg body weight of 
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onasemnogene abeparvovec-xioi. An additional five patients aged >24 to <60 months 
were treated with 1.2 X 10^14 vector genomes/kg body weight of onasemnogene 
abeparvovec-xioi. All treated individuals showed a gain in motor milestones achieved 
(i.e., rolling from back to sides, standing without support, walking without support) and 
there were no safety or tolerability concerns regarding the onasemnogene abeparvovec-
xioi (Finkel et al., 2019).  
Finally, in an open-label phase III clinical trial (SPR1NT) individuals with 
presymptomatic SMA and two or three copies of SMN2 were treated with onasemnogene 
abeparvovec-xioi. These presymptomatic individuals showed age-appropriate 
achievement of motor milestones and motor function after treatment (Schultz et al., 
2019). 
Nusinersen vs. Onasemnogene abeparvovec-xioi 
Dabbous et al. (2019) indirectly compared previously published data about infants 
with SMA Type I and two copies of SMN2 treated with nusinersen in the ENDEAR 
clinical trial to data about infants with SMA Type I and two copies of SMN2 treated with 
onasemnogene abeparvovec-xioi in the START clinical trial. Looking at the overall 
survival for these infants, Dabbous et al. concluded that the likelihood of preventing 
death was 20% higher for those treated with onasemnogene abeparvovec-xioi. They also 
concluded that infants treated with onasemnogene abeparvovec-xioi might have more 
independence from permanent ventilation, improved motor function, and an increase in 
the number of motor milestones achieved than infants treated with nusinersen. They 
recommend long-term monitoring of patients treated with onasemnogene abeparvovec-




If an individual with SMA is not treated with nusinersen or onasemnogene 
abeparvovec-xioi, supportive care may be used to manage the clinical course of the 
disease. Respiratory support involves medications and techniques that mechanically 
enhance a patient’s cough for the clearance of respiratory secretions (Kolb et al., 2017). 
Additionally, hypoventilation is prevented with devices that increase ventilation during 
sleep or periods of illness (Kolb et al., 2017). Nutritional support includes interventions 
to control gastroesophageal reflux, improve digestion, and minimize constipation. For 
patients with poor suck and swallowing issues, in addition to speech and feeding therapy, 
the use of a nasogastric tube or surgically placed feeding tube may be necessary (DiVito 
& Konek, 2010; Mercuri et al., 2018b). Physical therapy, occupational therapy, and 
bracing are used to prevent and treat contractures and scoliosis. Furthermore, some 
patients require surgery for internal spinal fixation (Iannaccone, 2007; Mercuri et al., 
2018b; Wang et al, 2007). 
Quality of Life 
Definition 
Vaidya and Boes (2018) define quality of life as “an individual’s perception of 
their position in life in the context of the culture and value systems in which they live and 
in relation to their goals, expectations, standards, and concerns” and state it is important 
to take into account when assessing a patient’s overall health. They also define health-
related quality of life as “the degree to which a medical condition impacts the physical, 
emotional, and social well-being of an individual” (Vaidya & Boes, 2018). For the 
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purpose of this literature review, quality of life and health-related quality of life are used 
as an interchangeable concept. 
Evaluating Quality of Life Within SMA 
The two instruments used most frequently in SMA quality of life research are the 
Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL GCS) and the 
Pediatric Quality of Life 3.0 Neuromuscular Module (PedsQL NMM). Therefore, this 
review of the present literature excludes studies that evaluate quality of life of children 
with SMA using other measurement tools. Additionally, because the present study is 
about the quality of life of children treated with nusinersen, onasemnogene abeparvovec-
xioi, both nusinersen and onasemnogene abeparvovec-xioi, or supportive care, studies 
that evaluate the quality of life of children with SMA treated with other experimental 
medications are excluded from this literature review. The PedsQL GCS measures health 
related quality of life in healthy populations and populations where patients have acute or 
chronic health conditions. It contains questions about physical, emotional, social, and 
school functioning. The PedsQL NMM measures health related quality of life in patients 
with neuromuscular diseases. It contains questions about the patient’s neuromuscular 
disease and ability to communicate as well as questions regarding family resources. Both 
instruments allow for patient self-assessment (PSA) and caregiver proxy-assessment 
(CPA). Table 1.1 contains information about previous research completed regarding the 
quality of life of children with SMA that use the PedsQL GCS and/or the PedsQL NMM. 






The quality of life of children with SMA has been investigated previously; 
however, there is no apparent literature published that directly compares parents’ 
perspectives of the quality of life of their children with SMA who received supportive 
care, nusinersen, onasemnogene abeparvovec-xioi, and those treated with a combination 
of both nusinersen and onasemnogene abeparvovec-xioi. 
Committee Opinion Number 691, “Carrier Screening for Genetic Conditions”, 
published by the American College of Obstetricians and Gynecologists (ACOG) in 
conjunction with the addition of SMA to the Recommended Uniform Screening Panel 
(RUSP), which is used as a guideline for state universal newborn screening programs, is  
support for the present study. ACOG (2017) recommends the following:  
Screening for spinal muscular atrophy should be offered to all women who are 
considering pregnancy or are currently pregnant. In patients with a family history 
of spinal muscular atrophy, molecular testing reports of the affected individual 
and carrier testing of the related parent should be reviewed, if possible, before 
testing. If the reports are not available, SMN1 deletion testing should be 
recommended for the low-risk partner. (p. 2) 
It is important for genetic counselors, genetic professionals, and other healthcare 
providers to be knowledgeable regarding parents’ perspectives of the quality of life of 
their children with SMA who have received supportive care, nusinersen, onasemnogene 
abeparvovec-xioi, and those treated with both nusinersen and onasemnogene 
abeparvovec-xioi. Knowing how quality of life perspectives differ based on the type of 
treatment received can help genetics professionals educate parents who are found to be 
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carriers for SMA and are at risk of having an affected child, or who have a child that has 
been diagnosed with SMA. Additionally, quality of life research helps to inform about 
the implications of disease on the patient and the patient’s family.  
Purpose 
The aim of the present study is to directly compare parents’ perspectives 
regarding the quality of life of their children with SMA, both living and deceased, who 
received or are currently receiving supportive care, nusinersen, onasemnogene 
abeparvovec-xioi, or treatment with both nusinersen and onasemnogene abeparvovec-
xioi. We predict that parents of children with SMA who received or are currently 
receiving treatment with nusinersen and/or onasemnogene abeparvovec-xioi will score 
their children’s quality of life higher than parents whose children received or are 






Table 1.1 Previous Research Investigating the Quality of Life of Individuals with SMA  
Table adapted from (Landfeldt et al., 2019). Studies that used instruments other than the PedsQL GCS and PedsQL NMM and studies 
that evaluated experimental medications other than nusinersen and onasemnogene abeparvovec-xioi were excluded. 
 
Authors (Year) Patient Sample 
Instrument(s) 
(PSA and CPA) 
Main Finding(s) 
Iannaccone, Hynan & 
Group, 2003 
33 US patients PedsQL NMM  
Patients had impaired quality of life across all 
instrument domains. 
Iannaccone et al., 
2009 
125 US patients 
PedsQL NMM 
PedsQL GCS 
Patients had impaired quality of life across all 
instrument domains. Agreement between PSAs 
and CPAs was moderate to poor. 
Kaufmann et al., 
2012 
57 US patients with type II or 
III 
PedsQL GCS 
Patients had impaired quality of life across all 
instrument domains. Instrument scores were 
markedly different across SMA type. 
Kocova, Dvorackova, 
Vondracek, & 
Haberlova, 2014  
35 Czech patients; 11% type I, 
66% type II, and 23% type III 
PedsQL NMM 
Patients had impaired quality of life across all 
instrument domains, and lower scores compared 
with US reference data. 
Klug et al., 2016 
189 German patients; 6% type 
I, 39% type II, and 55% type III 
PedsQL NMM 
Patient quality of life was impaired across all 
instrument domains and inversely associated with 
SMA type. 
Chiriboga et al, 2016  
28 US patients; 54% type II and 
46% type III 
PedsQL NMM 
PedsQL GCS 
No statistically significant changes in quality of 
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Purpose: To directly compare parents’ perspectives of the quality of life of their 
children with Spinal Muscular Atrophy (SMA) who received supportive care, nusinersen 
(Spinraza®), onasemnogene abeparvovec-xioi (Zolgensma®), or both nusinersen and 
onasemnogene abeparvovec-xioi. Methods: The parents of children with SMA were 
recruited to complete anonymous online surveys. All surveys included qualitative 
questions about quality of life. Surveys regarding children in the 1-12-month and 13-24-
month age groups included the Pediatric Quality of Life Infant Scales assessment. 
Surveys regarding children in the 2-4-year age group included the Pediatric Quality of 
Life Inventory 4.0 Generic Core Scales and the Pediatric Quality of Life 3.0 
Neuromuscular Module assessments. The >4-year age group did not include a 
quantitative quality of life assessment. Results: The 1-12-month age group average 
physical quality of life summary score was increased for children treated with a 
combination of both nusinersen and onasemnogene abeparvovec-xioi and also those 
treated with onasemnogene abeparvovec-xioi only. The 1-12-month- age group average 
psychosocial quality of life summary score was increased for children treated with 
nusinersen only. Conclusion: It was not possible to identify and associate a single 
treatment with conferring a statistically higher quality of life; however, the quantitative 
and qualitative responses collected allowed for an inference that parents believe their 
children with SMA have a greater quality of life when provided treatment over having 
only supportive care. Before the FDA approval of the available treatments, healthcare 
providers who shared the diagnosis of SMA with parents had to also share that there was 
no known effective treatment. However, today when families hear the diagnosis of SMA, 
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they can be hopeful for their child and family’s future because of the treatments available 
and the proven increase in quality of life with these treatments. Knowing how quality of 
life perspectives differ based on the type of treatment received can help in the education 
of parents of children with SMA. 
Introduction 
Spinal Muscular Atrophy (SMA) is the leading genetic cause of mortality in 
infants (Vaidya & Boes, 2018). SMA is an autosomal recessive disease characterized by 
spinal cord motor neuron degeneration, skeletal muscle atrophy, and generalized 
weakness involving the limbs, bulbar, and respiratory muscles (Chiriboga et al, 2016; 
Wirth et al., 2020). There are five types of SMA that can be historically classified based 
on age of symptom onset and achieved motor abilities (Rao et al., 2018; Vaidya & Boes, 
2018; Wirth et al., 2020). 
SMA is caused by homozygous loss of function mutations in the survival motor 
neuron one (SMN1) gene that encodes the survival motor neuron (SMN) protein (Finkel 
at al., 2016). A similar gene, survival motor neuron two (SMN2), has a coding sequence 
identical to that of the SMN1 gene, except for five nucleotides (Wirth et al, 2020). 
Specifically, a C to T substitution within exon seven of SMN2 (c.840C>T) causes this 
exon to be spliced out of SMN2 mRNA transcripts 90% of the time, resulting in an 
unstable SMN protein that is rapidly degraded instead of the full-length SMN protein. It 
is estimated that a full-length SMN protein results from SMN2 approximately 10% of the 
time as about 10% of SMN2 mRNA transcripts include exon seven (Helmken et al., 2003; 
Lefebvre et al., 1995). The number of copies of SMN2 generally explains the phenotypic 
variability between the different types of SMA. The more copies of SMN2 an individual 
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has, the more SMN protein they produce. Those with a small amount of full-length SMN 
protein typically have more severe symptoms, and those with more full-length SMN 
protein typically have less severe symptoms (Chiriboga et al., 2016; Feldkötter et al, 
2002; Finkel et al., 2016; Mailman et al, 2002; Wirth et al., 2006). 
Treatments for SMA 
Nusinersen (Spinraza®) was the first FDA approved treatment for individuals with 
all types of SMA (Hoy, 2017). Nusinersen is an antisense oligonucleotide delivered 
through repeated intrathecal injections (Finkel et al., 2016). Treatment with nusinersen 
includes three 12mg loading doses given fourteen days apart with a fourth 12mg dose 
given thirty days after the third loading dose. Continued treatment with nusinersen 
includes an additional 12mg dose every four months for life (Hoy, 2017). Nusinersen 
functions by altering the splicing of SMN2 to promote the inclusion of exon seven in 
SMN2 mRNA transcripts, thereby increasing the amount of full-length SMN protein 
produced (Kolb et al., 2017). Treatment with nusinersen costs approximately $400,000-
500,000 in the first year and $250,000-300,000 per year thereafter for the duration of the 
treated individual’s lifetime (Wirth et al., 2020). 
Onasemnogene abeparvovec-xioi (Zolgensma®) was the second FDA approved 
treatment for patients with SMA type I under two years of age (Hoy, 2019). It consists of 
adeno-associated virus nine, which is modified to include a functional copy of the SMN1 
gene (Hoy, 2019). Introducing a functional copy of the SMN1 gene into an affected 
person’s motor neuron cells addresses the genetic cause of SMA and increases the 
amount of SMN protein present in the body (Mendell et al., 2017). The dosing of 
onasemnogene abeparvovec-xioi is 1.1 × 1014 vector genomes/kg body weight 
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administered over 60 minutes as a single intravenous infusion. Treatment with a single 
injection of onasemnogene abeparvovec-xioi costs two million US dollars (Wirth et al., 
2020). 
Dabbous et al. (2019) indirectly compared previously published data about infants 
with SMA Type I and two copies of SMN2 treated with nusinersen in the ENDEAR 
clinical trial to data about infants with SMA Type I and two copies of SMN2 treated with 
onasemnogene abeparvovec-xioi in the START clinical trial. Looking at the overall 
survival for these infants, Dabbous et al. concluded that the likelihood of preventing 
death was 20% higher for those treated with onasemnogene abeparvovec-xioi. They also 
concluded that infants treated with onasemnogene abeparvovec-xioi might have more 
independence from permanent ventilation, improved motor function, and an increase in 
the number of motor milestones achieved than infants treated with nusinersen. They 
recommend long-term monitoring of patients treated with onasemnogene abeparvovec-
xioi to confirm these conclusions.  
If an individual with SMA is not treated with nusinersen or onasemnogene 
abeparvovec-xioi, supportive care may be used to manage the clinical course of the 
disease. Respiratory support involves medications and techniques that mechanically 
enhance a patient’s cough for the clearance of respiratory secretions (Kolb et al., 2017). 
Additionally, hypoventilation is prevented with devices that increase ventilation during 
sleep or periods of illness (Kolb et al., 2017). Nutritional support includes interventions 
to control gastroesophageal reflux, improve digestion, and minimize constipation. For 
patients with poor suck and swallowing issues, in addition to speech and feeding therapy, 
the use of a nasogastric tube or surgically placed feeding tube may be necessary (DiVito 
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& Konek, 2010; Mercuri et al., 2018b). Physical therapy, occupational therapy, and 
bracing are used to prevent and treat contractures and scoliosis. Furthermore, some 
patients require surgery for internal spinal fixation (Iannaccone, 2007; Mercuri et al., 
2018b; Wang et al., 2007). 
Quality of Life 
Vaidya and Boes (2018) define quality of life as “an individual’s perception of 
their position in life in the context of the culture and value systems in which they live and 
in relation to their goals, expectations, standards, and concerns” and state it is important 
to take into account when assessing a patient’s overall health. They also define health-
related quality of life as “the degree to which a medical condition impacts the physical, 
emotional, and social well-being of an individual” (Vaidya & Boes, 2018). For the 
purpose of this study, quality of life and health-related quality of life are used as an 
interchangeable concept. 
The two instruments used most frequently in SMA quality of life research are the 
PedsQL GCS and the PedsQL NMM. The PedsQL GCS measures health related quality 
of life in healthy populations and populations where patients have acute or chronic health 
conditions. The PedsQL NMM measures health related quality of life in patients with 
neuromuscular diseases. Previous research completed regarding the quality of life of 
children with SMA using the PedsQL GCS and/or the PedsQL NMM consistently show 
that children with SMA have an impaired quality of life (Landfeldt et al., 2019).  
Rationale  
The quality of life of children with SMA has been investigated previously; 
however, there is no apparent literature published that directly compares parents’ 
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perspectives of the quality of life of their children with SMA who received supportive 
care, nusinersen, onasemnogene abeparvovec-xioi, and those treated with a combination 
of both nusinersen and onasemnogene abeparvovec-xioi. 
Committee Opinion Number 691, “Carrier Screening for Genetic Conditions”, 
published by the American College of Obstetricians and Gynecologists (ACOG) in 
conjunction with the addition of SMA to the Recommended Uniform Screening Panel 
(RUSP), which is used as a guideline for state universal newborn screening programs, is 
support for the present study. ACOG (2017) recommends the following:  
Screening for spinal muscular atrophy should be offered to all women who are 
considering pregnancy or are currently pregnant. In patients with a family history 
of spinal muscular atrophy, molecular testing reports of the affected individual 
and carrier testing of the related parent should be reviewed, if possible, before 
testing. If the reports are not available, SMN1 deletion testing should be 
recommended for the low-risk partner. (p. 2) 
It is important for genetic counselors, genetic professionals, and other healthcare 
providers to be knowledgeable regarding parents’ perspectives of the quality of life of 
their children with SMA who have received supportive care, nusinersen, onasemnogene 
abeparvovec-xioi, and those treated with both nusinersen and onasemnogene 
abeparvovec-xioi. Knowing how quality of life perspectives differ based on the type of 
treatment received can help genetics professionals educate parents who are found to be 
carriers for SMA and are at risk of having an affected child, or who have a child that has 
been diagnosed with SMA. Additionally, quality of life research helps to inform about 




The aim of the present study is to directly compare parents’ perspectives 
regarding the quality of life of their children with SMA, both living and deceased, who 
received or are currently receiving supportive care, nusinersen, onasemnogene 
abeparvovec-xioi, or treatment with both nusinersen and onasemnogene abeparvovec-
xioi. We predict that parents of children with SMA who received or are currently 
receiving treatment with nusinersen and/or onasemnogene abeparvovec-xioi will score 
their children’s quality of life higher than parents whose children received or are 
currently receiving only supportive care. 
Methods 
Participants and Recruitment 
The aim of this research was to directly compare parents’ perspectives regarding 
the quality of life of their children with SMA. Therefore, participation was limited to the 
parents of children with SMA. This study included parents of children who were 
deceased in order to incorporate data from a population whose children might have only 
received supportive care. 
Recruitment for this study was conducted with the aid of the Gwendolyn Strong 
Foundation (GSF), a non-profit dedicated to advocating for individuals and families with 
SMA, supporting SMA research, and promoting inclusion for all people living with a 
disability or genetic condition. The survey used was advertised through social media 
postings on the GSF Facebook page and stories (https://www.facebook.com/endsma/), 
Instagram account and stories (https://www.instagram.com/nevergiveuporg/), Twitter 
account (https://twitter.com/nevergiveuporg), and website (https://nevergiveup.org) 
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(Appendix A & Figure 2.1). Survey responses were recorded from August 21st, 2019 to 
September 26th, 2019. To incentivize participation, individuals could enter a raffle to win 
a $50 Amazon gift card and t-shirt from the GSF. In order to enter the raffle, participants 
provided their email address that also served as their consent to be contacted if they were 
selected as the winner. At the end of the survey period, all raffle entries were entered into 
an online software which randomly selected a winner. To avoid coercion, we did not 
provide any direct financial or academic compensation for participation in this study.  
Participation in this study was voluntary. The survey welcome page detailed the 
purpose of the study, eligibility requirements, and information addressing informed 
consent (Appendix B). It was stated that participants could withdraw from the study at 
any time by not completing all of the survey questions, and that informed consent was 
provided upon completion of the survey. To establish participant eligibility and for 
determination of the correct survey for participants to complete, there were several 
screening questions at the beginning of the survey. Individuals who did not meet 
participation eligibility were automatically directed to the end of the survey.  
A total of 333 individuals attempted to complete the online survey. Thirty-four 
individuals were excluded because they indicated they were not the parent of a child with 
SMA. Two hundred ninety-nine individuals indicated that they were the parent of a child 
with SMA and were directed to the next question. The next question asked participants if 
their child with SMA was living or deceased in order to direct them to a tense appropriate 
survey. If participants declined to answer this question, they were not allowed to move 
forward to complete the survey. There were two participants that declined to answer this 
question and were manually excluded from the study. An additional two survey responses 
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were manually excluded because participants completed surveys that were not 
appropriate for their child’s age. Furthermore, six surveys were also excluded because 
participants did not complete greater than 50% of the quality of life assessment questions 
that were necessary for the calculation of quality of life scores. Also, 58 incomplete 
surveys were manually excluded as a completed survey was required for informed 
consent. In total, 231 survey responses were included in the final analysis. Of the 231 
responses, 206 were regarding living children, and 25 were regarding deceased children. 
The survey exclusion process is summarized in Figure 2.2. 
Instrument 
Participants completed web-based surveys developed through Qualtrics.comXM. 
Three quality of life instruments were used in this study. The first two instruments were 
the PedsQL GCS and the PedsQL NMM (Iannaccone et al., 2009; Varni, Burwinkle, 
Seid, & Skarr, 2003). They are quality of life instruments that have been validated with 
SMA populations and are used most frequently in SMA quality of life research 
(Iannaccone et al., 2009; Landfeldt et al., 2019). The PedsQL GCS contains questions 
about physical, emotional, social, and school functioning. The PedsQL NMM contains 
questions about the patient’s neuromuscular disease and ability to communicate as well 
as questions regarding family resources. While both instruments allow for patient self-
assessment (PSA) and caregiver proxy-assessment (CPA), they are only validated for 
individuals over two years of age (Landfeldt et al., 2019). Due to the fact that 
onasemnogene abeparvovec-xioi is only FDA approved for children under the age of two, 
it was important that this study included an instrument that measured the quality of life of 
children under the age of two. As there is no quality of life instrument validated for 
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children with SMA who are younger than two years old, the third quality of life 
instrument used in this study was the PedsQL Infant Scales (PedsQL IS) (Varni et al., 
2011). The PedsQL IS uses CPAs to measure health related quality of life in healthy 
infants and infants who have acute or chronic health conditions. It contains questions 
about physical symptoms and physical, emotional, social, and cognitive functioning.  
There were eight separate but similar surveys available for participants to 
complete (Appendices C-J). All of the surveys contained questions about the child’s 
current age or age when he/she passed away, treatment(s) given, the number of copies of 
SMN2 they have/had, etc. Surveys C, D, E, and F, regarding children <24 months of age, 
were created using the PedsQL IS with permission from eProvide. Surveys C and D had a 
reliability score of 0.894 and surveys E and F had a reliability score of 0.791. Surveys G 
and H, regarding children in the 2-4-year age group, were created using the PedsQL GCS 
and PedsQL NMM with permission from eProvide. Surveys I and J, regarding children 
>4-years of age, did not include a published quality of life instrument because 
onasemnogene abeparvovec-xioi is only FDA approved for children under the age of two 
and considering the timing of this study and the approval of onasemnogene abeparvovec-
xioi it would be highly unlikely for children in this age group to have received this 
treatment. Table 2.1 details the instruments used in each survey as well as the intended 
participants for each survey. 
Surveys utilized the appropriate tense for parents whose children were deceased. 
For example, parents of a child who died would read, “How old was your child when 
he/she passed away?” instead of reading, “How old is your child?”. Skip logic was 
utilized to ensure participants received surveys that had the appropriate tense and were 
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for the correct age of their child. Figures 2.3 - 2.6 show how many surveys were taken 
about children in each age category and the type of treatments the children received.  
Data Analysis 
Qualtrics.comXM software was used to collect all data. The Scaling and Scoring of 
the PedsQL published instructions were used in the analysis of the PedsQL IS, PedsQL 
GCS, and PedsQL NMM instruments with permission from eProvide (Varni, 2017). 
Microsoft® Excel and Laerd Statistics were used in the analysis of data. Statistical 
analyses were reported in APA style. Alpha was calculated for scales C, D, E, and F. A 
grounded theory approach was used to analyze the qualitative data collected from open-
ended questions. 
Results 
Parent Reported Quality of Life of Children Aged 1-12 Months 
A one-way Welch ANOVA was conducted to determine if parent proxy scores 
regarding their children’s physical quality of life was different for those in the 1-12-
month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both 
nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were 
classified into four groups: nusinersen only (n=10), onasemnogene abeparvovec-xioi only 
(n=12), both nusinersen and onasemnogene abeparvovec-xioi (n=4), and supportive care 
(n=17). The differences between the physical quality of life scores between these groups 
were statistically significantly different, Welch’s F(3, 39) = 12.222, p < .001. Visual 
analysis revealed that the mean physical quality of life summary score increased for 
children treated with a combination of both nusinersen and onasemnogene abeparvovec-
xioi (M = 69.270, SD = 2.604) and those treated with onasemnogene abeparvovec-xioi 
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only (M =70.937, SD = 1.145) compared to children treated with nusinersen only (M = 
55.671, SD = 3.356), and those with supportive care (M = 55.458, SD = 11.916). The 
average physical summary scores regarding children aged 1-12-months who received 
different interventions is shown in Figure 2.7. 
A second one-way Welch ANOVA was conducted to determine if parent proxy 
scores regarding their children’s psychosocial quality of life was different for those in the 
1-12-month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both 
nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were 
classified into four groups: nusinersen only (n=10), onasemnogene abeparvovec-xioi only 
(n=12), both nusinersen and onasemnogene abeparvovec-xioi (n=4), and supportive care 
(n=17). The differences between the psychosocial quality of life scores between these 
groups were statistically significantly different, Welch’s F(3, 39) = 12.163, p < .001. 
Visual analysis revealed that the mean psychosocial quality of life summary score 
increased for children treated with nusinersen only (M = 87.268, SD = 3.285) compared 
to those treated with onasemnogene abeparvovec-xioi only (M = 68.914, SD = 9.1333), 
both nusinersen and onasemnogene abeparvovec-xioi (M = 71.701, SD = 8.038), and 
supportive care (M = 74.137, SD = 7.596). The average psychosocial summary scores 
regarding children aged 1-12-months who received different interventions is shown in 
Figure 2.8.  
Parent Reported Quality of Life of Children Aged 13-24 Months 
A one-way Welch ANOVA was conducted to determine if parent proxy scores 
regarding their children’s physical quality of life was different for those in the 13-24-
month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both 
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nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were 
classified into four groups: nusinersen only (n=12), onasemnogene abeparvovec-xioi only 
(n=11), both nusinersen and onasemnogene abeparvovec-xioi (n=11), and supportive care 
(n=5). The mean physical quality of life summary score increased for children treated 
with both a combination of nusinersen and onasemnogene abeparvovec-xioi (M = 62.739 
, SD = 12.487) and those treated with onasemnogene abeparvovec-xioi only (M = 65.517, 
SD = 11.982) compared to children treated with nusinersen only (M = 58.492 , SD = 
11.299) and those with supportive care (M = 54.444, SD = 9.305); however, the 
differences between these groups were not statistically significant, Welch’s F(3,35 ) = 
1.345 , p = .276. The average physical summary scores regarding children aged 13-24-
months who received different interventions is shown in Figure 2.9.
A final one-way Welch ANOVA was conducted to determine if parent proxy 
scores regarding their children’s psychosocial quality of life was different for those in the 
13-24-month age group treated with nusinersen, onasemnogene abeparvovec-xioi, both 
nusinersen and onasemnogene abeparvovec-xioi, or supportive care. Participants were 
classified into four groups: nusinersen only (n=12), onasemnogene abeparvovec-xioi only 
(n=11), both nusinersen and onasemnogene abeparvovec-xioi (n=11), and supportive care 
(n=5). The differences between the average psychosocial quality of life summary scores 
for children treated with nusinersen only (M = 68.773, SD = 7.261), onasemnogene 
abeparvovec-xioi only (M = 75.722, SD = 8.477), both nusinersen and onasemnogene 
abeparvovec-xioi (M = 73.512, SD = 8.504), and supportive care (M = 71.076, SD = 
12.897) were not statistically significant, Welch’s F(3, 35) = 1.309, p = .287. The average 
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psychosocial summary scores regarding children aged 13-24-months who received 
different interventions is shown in Figure 2.10. 
Parent Reported Quality of Life of Children Aged 2-4 Years 
Of the 28 surveys taken about children with SMA in the 2-4-year age group, 26 
were regarding children who received only nusinersen, one was about a child who 
received onasemnogene abeparvovec-xioi only, and one was about a child who received 
both nusinersen and onasemnogene abeparvovec-xioi. To eliminate the possibility of 
identifying the one child who received onasemnogene abeparvovec-xioi only and the 
other child who received both nusinersen and onasemnogene abeparvovec-xioi, all 
quality of life data regarding children in the 2-4-year age group was not analyzed and is 
not reported. 
Parent Reported Quality of Life of Children Aged >4 Years 
Of the 121 surveys taken about children with SMA in the >4-year age group, 22 
were regarding children who received supportive care, 98 were about children who 
received nusinersen, and one was about a child who received onasemnogene 
abeparvovec-xioi only. To eliminate the possibility of identifying the one child in this age 
group who received onasemnogene abeparvovec-xioi only, the survey about this child 
was excluded from the data analysis. Qualitative quality of life responses regarding the 
22 children who received supportive care and the 98 children who received nusinersen 
were analyzed.  
Qualitative Quality of Life Responses 
In each survey parents were provided the opportunity to answer a free response 
question and provide information about their children’s quality of life, the treatments, etc. 
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Listed below are a few quotes from parents regarding the quality of life of their children 
who received supportive care. 
1. “He was unable to nurse after birth and a g-tube was placed shortly after. He was 
excellent at following movements with his eyes, but shortly after birth lost his 
moro reflex. He would cry if he had been held too long. He used his accessory 
muscles to help breathe from birth and at 12 weeks had his first collapsed lung.” 
2. “SMA took its natural course as far as progression goes. Despite following 
dietary and respiratory protocols, she needed to be trached and lost all 
movement.” 
3. “My son passed away almost twelve years ago at nine months old. He was 
diagnosed at six months old with SMA Type 1. His diagnosis was devastating. The 
team of doctors at [hospital] said that he was showing symptoms for one of two 
illnesses: Botulism or SMA. The same week he was treated for botulism and we 
were told that if he were diagnosed with SMA, it would be unlikely for him to 
reach his first birthday. I didn’t research the disease for those excruciating five 
weeks while we waited for diagnosis results. I believed I saw improvement with 
the help of physical therapy. Then we were given the grim diagnosis, no 
treatment. No options. We were sent home, we loved on sweet little [name] in big 
ways those next three months. Pneumonia became a chronic illness for him, and 
we were placed on hospice and palliative care as patients on the pediatric floor 
for just shy of three months. My son’s brave spirit and joy he shared with those 
who knew him are forever cherished. Families today have hope with this 
diagnosis. They have choices and options to improve their children’s quality of 
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life and life expectancy. What a gift this research has been. From the bottom of 
my heart, thank you.” 
4. “There was no treatment available. Doctors told us we had six months with her 
[and we should] take her home and love her. Regarding our genetic counseling 
experience, frankly, it was worthless. My daughter attended the session and there 
absolutely zero information gained from the appointment. It was a waste of time 
and very disappointing. Thank you for your efforts in trying to improve this 
area.” 
Listed below are a few quotes from parents regarding the quality of life of their children 
who received nusinersen (Spinraza®). 
5. “Our child's natural disposition seems to be happy, social, [and] determined. 
Coupled with treatment, it has helped us all stay positive.” 
6. “[Name] has an excellent quality of life. [He] is a very positive child who loves 
life, has many friends, and truly believes he can do everything.” 
7. “My child has a wonderful quality of life and is one of the happiest persons I 
know.” 
8. “As parents, we can see improvement in his hands and arms after 4 doses.” 
9. “[Name’s] quality of life has improved w[ith] Spinraza. He is able to sit up in his 
chair longer and breathes better. He is also able to hold things in his hands, move 
his legs, and move his head from side to side. He definitely tells us he feels like he 
has more energy since starting Spinraza.” 
10. “Before Spinraza we were in hospital a lot. Started Spinraza at 29 months and 
he's now 48 months old. Since 29 months of age, we have had only two hospital 
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admissions lasting 1-2 days each, compared to two-week admissions before 
Spinraza. He has shown mostly respiratory improvements.” 
11. “He has had 10 doses of Spinraza, and it has helped with lung function. Before 
Spinraza cough sessions would take 2+ hours, now they only take 20 minutes!” 
12. “My child’s quality of life has improved since starting Spinraza treatments. Her 
stamina has improved, her voice is louder, her hand now has the stamina and 
strength to play independently on her iPad for hours.” 
13. “[Name] has been taking Spinraza for [a] year and a half. Although it may seem 
like small gains, his voice is louder, his enunciation is better, he has a productive 
cough, he has more stamina and is better able to drive his power chair.  There are 
many other feats that have improved as well.” 
14. “Not having accessible transportation makes it difficult for us. She can’t be an 
active member of our community.” 
15. “Mobility, accessibility and acceptance are my biggest fears for [name].” 
16. “With age I fear the lack of inclusiveness around her might not make her feel as 
content as she now.” 
17. “Dealing with her disease has been life-altering in every aspect I can think of. It 
has been incredibly and profoundly difficult and has changed our family in ways 
that are difficult to explain. [Name] has lived an incredible life...we have found 
ways around her disability every opportunity we can. It is also been very 
isolating. I feel that despite her physical limitations, she has lived a very happy 
and amazing life.” 
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18. “[Name] is a very energetic 5-year-old boy who loves everything about life. 
Hates when people treat him like he is disabled! Loves aqua therapy, horses, 
dinosaurs, [and] most of all playing soccer with his brother. Since starting 
Spinraza [name] has been able to lift his legs off of the bed to do ‘kissing knees’ 
and has a new goal to be able to ride a bike very soon.” 
Listed below are a few quotes from parents regarding the quality of life of their children 
who received onasemnogene abeparvovec-xioi (Zolgensma®). 
19. “Our child has maxed out the Chop-intend at 3 months of age and has met all 
milestones so far, some even early. She is able to sit unassisted briefly and roll in 
both directions. She is also able to pull herself toward objects. The only 
indication of SMA symptoms presenting this far is slight aspiration on formula if 
rice cereal is not added. She received treatment at 3 months old.” 
20. “[Name] was treated with Zolgensma 7 days ago! We are already seeing new 
strength in him!” 
21. “He has an amazing quality of life. We keep him involved with anything an able-
bodied person would do, just modified.”  
Listed below are a few quotes from parents regarding the quality of life of their children 
who received both nusinersen (Spinraza®) and onasemnogene abeparvovec-xioi 
(Zolgensma®). 
22. “The treatments have been amazing for my child.” 
23. “Has made some movement gains.” 
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24. “Since starting Spinraza in April and then receiving Zolgensma in July, my son is 
improving rapidly. He gained back the skills he lost and is now even starting to 
stand with his braces/support.” 
Discussion 
In this study we set out to directly compare parents’ perspectives regarding the 
quality of life of their children with SMA, both living and deceased, who received or are 
currently receiving supportive care, nusinersen, onasemnogene abeparvovec-xioi, or 
treatment with both nusinersen and onasemnogene abeparvovec-xioi. While the quality of 
life of children with SMA has been investigated previously, there is no apparent literature 
published that directly compares parents’ perspectives of the quality of life of their 
children with SMA who have received these interventions. We predicted that parents of 
children with SMA who received or are currently receiving treatment with nusinersen 
and/or onasemnogene abeparvovec-xioi would score their children’s quality of life higher 
than parents whose children received or are currently receiving only supportive care. 
Considering the present data, it is not possible to identify and associate a single treatment 
with conferring a statistically higher quality of life; however, the quantitative and 
qualitative responses collected allow for an inference that parents believe their children 
with SMA have a greater quality of life when provided treatment over having only 
supportive care. 
Physical Quality of Life 
The physical quality of life summary scores regarding children in the 1-12-month 
and 13-24-month age groups were an average of parents’ answers to questions about their 
children’s physical symptoms and physical functioning. In the 1-12-month age group 
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physical summary scores were increased, indicating greater quality of life, for children 
treated solely with onasemnogene abeparvovec-xioi and for children treated with both 
nusinersen and onasemnogene abeparvovec-xioi. Interestingly, while clinical trials have 
proven the effectiveness of nusinersen on improving physical functioning and motor 
abilities, children in this age group treated with nusinersen received low physical quality 
of life summary scores that were equivalent to the scores regarding children who received 
supportive care. Furthermore, while the differences between the physical quality of life 
summary scores regarding children in the 13-24-month age group were not statistically 
significant, it is important to note that for children in this age group, physical quality of 
life scores followed the same pattern recorded for the 1-12-month age group (increased 
for those treated with solely onasemnogene abeparvovec-xioi and also those treated with 
both nusinersen and onasemnogene abeparvovec-xioi and low for children treated with 
nusinersen and supportive care). 
Considering these results, it may be that parents of children treated with 
nusinersen in the 1-12-month and 13-24-month age groups were thinking about their 
children’s adverse reactions to the treatment when completing the quality of life 
assessment. Finkel et al. (2017) observed adverse reactions such as constipation and 
respiratory tract infections in both patients treated with nusinersen and those given a 
sham-procedure. Furthermore, parents of children treated with nusinersen in the 1-12-
month and 13-24-month age groups may believe their children have a lower physical 
quality of life because of the repeated intrathecal injections required in the administration 
of this treatment. It is important to consider that children treated with nusinersen in these 
age groups would either be in their first year or would have just finished their first year of 
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treatment that involves the highest number of intrathecal injections (three 12mg loading 
doses given fourteen days apart, a fourth 12mg dose given thirty days after the third 
loading dose, and continued treatment with a 12mg dose every four months). The 
repeated intrathecal injections may also be the reason why parents of children in these 
age groups treated with both nusinersen and onasemnogene abeparvovec-xioi scored their 
children’s physical quality of life slightly lower than those treated with only 
onasemnogene abeparvovec-xioi, which does not involve any intrathecal injections.  
The qualitative responses from parents of children in the 1-12-month and 13-24-
month age groups treated with nusinersen are uninformative in terms of physical quality 
of life as participants detailed their children’s diagnosis stories, their efforts for 
onasemnogene abeparvovec-xioi to be covered by their children’s insurance, and their 
appreciation for this study giving attention to the SMA community. The qualitative 
responses from parents of children in the >4-year age group treated with nusinersen 
however contradict the low physical quality of life scores recorded in the 1-12-month and 
13-24-month age groups. Many parents of children in the >4-year age group shared that 
since their children started nusinersen they had seen improvements in respiratory 
function, motor abilities, and energy. Several participants also commented on a decrease 
in the amount and length of hospitalizations their children had since starting nusinersen. 
Al-Zaidy et al (2019) hypothesized that decreased hospitalizations of patients treated with 
onasemnogene abeparvovec-xioi was associated with an alleviation of patient and 
caregiver burden and could be associated with an improved quality of life, therefore we 
hypothesize that decreased hospitalizations of children treated with nusinersen might also 
be associated with an alleviation of patient and caregiver burden and could also be 
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associated with an improved quality of life. The low physical quality of life scores 
regarding children in the 1-12-month and 13-24-month age group and the lack of 
qualitative responses regarding physical quality of life for these children leave us with the 
hypothesis that the intrathecal injections necessary in the first year of treatment with 
nusinersen is a large contributing factor in parents’ perspectives of their children’s 
physical quality of life.  
Psychosocial Quality of Life 
The psychosocial quality of life summary scores regarding children in the 1-12-
month and 13-24-month age group were an average of parents’ answers to questions 
about their children’s social, emotional, and cognitive functioning. Differences between 
psychosocial summary scores regarding children in the 1-12-month age group were 
statistically significant. Those treated solely with nusinersen had increased scores, 
indicating greater quality of life, compared to those that received onasemnogene 
abeparvovec-xioi only, both nusinersen and onasemnogene abeparvovec-xioi, and 
supportive care. The differences between psychosocial summary scores regarding 
children in the 13-24-month age group were not statistically significant and showed no 
recognizable pattern.  
At the time the survey became available to participants, onasemnogene 
abeparvovec-xioi only had FDA approval for 3 months, compared to nusinersen that had 
FDA approval for 32 months. Considering this difference, it is possible that parents of 
children treated with onasemnogene abeparvovec-xioi had only seen an initial physical 
improvement, because the treatment functions to directly increase the amount of SMN 
protein in the body, and they might not have seen a psychosocial improvement yet at the 
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time they completed the survey as psychosocial improvement may be related to one’s 
ability to move and interact in the community and environment. This theory is supported 
by the result that children treated with both nusinersen and onasemnogene abeparvovec-
xioi had slightly higher psychosocial quality of life scores compared to those that 
received onasemnogene abeparvovec-xioi only.  
It is important to note that two parent participants in the 1-12-month age group 
whose children received onasemnogene abeparvovec-xioi provided feedback that the 
quality of life assessment was difficult to complete. One parent stated that their child was 
young at one month and three weeks of age, so some of the assessment items were not 
applicable for them. They also stated that they did not realize they could skip questions 
and attempted to go backwards in the survey to deselect items but were unable to. The 
other parent stated that their child was six weeks old and received onasemnogene 
abeparvovec-xioi at four weeks of age, so they believed some of the questions did not 
apply to their child. After a review of the quality of life assessment these parents took, we 
conclude that the questions that contribute the physical quality of life summary scores 
apply equally to all children in the 1-12-month age group regardless of if they are 1 
month or 12 months in age. Interestingly, we conclude that the questions that contribute 
to the psychosocial quality of life summary scores do not apply equally to children that 
are 1 month of age the same way that they apply to children that are 12 months of age. 
We believe these two parents of children treated with onasemnogene abeparvovec-xioi 
most likely scored their children lower on the psychosocial questions by indicating that 
their children have trouble completing skills that they might not be expected to achieve 
yet when considering their age and typical development (i.e. making eye contact, 
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laughing, not imitating caregiver’s facial expressions and actions, etc.). Furthermore, it is 
possible that other parents participating in this study had this experience but did not 
provide feedback about it. 
The Phrase “No Treatment” and Genetic Counseling 
Nusinersen and onasemnogene abeparvovec-xioi were approved by the FDA as 
the first two treatments for SMA in 2016 and 2019 respectively. Before these treatments 
were available, individuals with SMA were provided supportive care for the management 
of disease progression and symptoms. Several parents of children who received 
supportive care shared about their heartbreak learning of the terminal diagnosis with no 
treatment, the natural disease progression SMA had on their child, and the fact that 
parents today are able to have hope because of the new treatments available. An example 
of one of these quotes from a parent whose child was in the 1-12-month age group is 
provided here: 
My son passed away almost twelve years ago at nine months old. He was 
diagnosed at six months old with SMA Type 1. His diagnosis was devastating. The 
team of doctors at [hospital] said that he was showing symptoms for one of two 
illnesses: Botulism or SMA. The same week he was treated for botulism and we 
were told that if he were diagnosed with SMA, it would be unlikely for him to 
reach his first birthday. I didn’t research the disease for those excruciating five 
weeks while we waited for diagnosis results. I believed I saw improvement with 
the help of physical therapy. Then we were given the grim diagnosis, no 
treatment. No options. We were sent home, we loved on sweet little [name] in big 
ways those next three months. Pneumonia became a chronic illness for him, and 
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we were placed on hospice and palliative care as patients on the pediatric floor 
for just shy of three months. My son’s brave spirit and joy he shared with those 
who knew him are forever cherished. Families today have hope with this 
diagnosis. They have choices and options to improve their children’s quality of 
life and life expectancy. 
While the surveys available to take in this study did not include any questions regarding 
parents’ genetic counseling experiences, one parent commented on the disappointing 
experience their family had: 
“There was no treatment available. Doctors told us we had six months with her 
[and we should] take her home and love her. Regarding our genetic counseling 
experience, frankly, it was worthless. My daughter attended the session and there 
absolutely zero information gained from the appointment. It was a waste of time 
and very disappointing.” 
Before the FDA approval of nusinersen and onasemnogene abeparvovec-xioi, genetic 
counselors, genetic professionals, and other healthcare providers who shared the 
diagnosis of SMA with parents had to also share about the natural history of the disease 
and that there was no known effective treatment. Yang et al. (2016) interviewed parents 
of children with SMA type I and II who received supportive care before FDA’s approval 
of nusinersen and onasemnogene abeparvovec-xioi to learn their experiences with 
anticipatory loss. From these interviews it was found that parents of children with SMA 
felt completely helpless because there was no known effective treatment; however, they 
also felt pressure to provide their children the best care possible. They also learned that 
parents initially seized every opportunity for exploratory treatments to extend their 
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children’s lives, however, as treatments consistently failed, they decided to spend more 
time cherishing their children’s brief lives using supportive care. However, today when 
families hear the diagnosis of SMA, they will no longer be told that there is nothing they 
can do and that they should take their children home and love them. Now, when a family 
hears a diagnosis of SMA, they can be hopeful for their child and family’s future because 
of the treatments available and the proven increase in quality of life with these 
treatments. It is important for genetic counselors, genetic professionals, and other 
healthcare providers to be knowledgeable about parents’ perspectives of the quality of 
life of their children with SMA who have received the various treatments because 
knowing how quality of life perspectives differ based on the type of treatment received 
can help them educate parents who are found to be carriers for SMA and are at risk of 
having an affected child, or who have a child that has been diagnosed with SMA. Data 
collected in this study undoubtedly helps inform about parents’ perspectives of the 
quality of life of their children with SMA who have received the various treatments.  
Limitations and Future research 
Due to the fact that onasemnogene abeparvovec-xioi is only FDA approved for 
children under the age of two, it was important that this study included an instrument that 
measured the quality of life of children in this age group, therefore the PedsQL IS was 
utilized. A limitation of this study is that the PedsQL IS assessment has not been used in 
SMA populations before, therefore we are not able to make a comparison of the data 
collected in this study using this assessment to previously published studies. An 
additional limitation of this study is that participants were only able to change, but not 
deselect items in the quantitative quality of life assessments. This technical issue is 
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important, because the questions in the PedsQL IS that contributed to the psychosocial 
quality of life summary scores do not apply equally to children that are 1 month of age 
the same way that they apply to children that are 12 months of age. We believe that at 
least two parents of children in the 1-12-month age group treated with onasemnogene 
abeparvovec-xioi scored their children lower on the psychosocial questions by indicating 
that their children have trouble completing skills that they might not be expected to 
achieve yet when considering their age and typical development (i.e. making eye contact, 
laughing, not imitating caregiver’s facial expressions and actions, etc.). Another 
limitation of this study is that data regarding the 2-4-year age group, which used the 
PedsQL GCS and PedsQL NMM assessments previously used in SMA quality of life 
research, was excluded to eliminate the possibility of identifying participants and 
therefore comparisons to previously published quality of life data using these assessments 
could not be made. Another limitation of this study is that within the data that was 
statistically significant (the 1-12-month age group) there was a small sample size with ten 
parents whose children had nusinersen only, twelve parents whose children had 
onasemnogene abeparvovec-xioi only, four parents whose children had both nusinersen 
and onasemnogene abeparvovec-xioi, and seventeen parents whose children had 
supportive care. A greater sample size may have allowed for more robust data from the 1-
12-month age group and statistically significant data from the 13-24-month age group 
and may have also allowed for inclusion of the data from the 2-4-year age group. 
Additionally, the free response qualitative quality of life question in each survey was too 
vague. If we included more specific qualitative quality of life questions such as, “please 
describe your child’s physical quality of life” and “please describe your child’s 
 
41 
psychosocial quality of life”, we may have received more detailed information from 
parents about their children’s quality of life. Furthermore, the quality of life of children 
without SMA was not assessed as a control group, therefore, the quality of life of 
children with SMA that received the various treatments could not be compared to the 
quality of life of unaffected, healthy children. Finally, although the aim of this study was 
to learn and directly compare parents’ perspectives of their children’s quality of life 
considering the various treatments, it is important to note that parents’ perceptions may 
be different from their children’s perceptions of their own quality of life as the affected 
individuals. 
This study undoubtedly contributes to our knowledge of parents’ perspectives of 
the quality of life of their children with SMA who have received the various interventions 
available. It also provides information about how quality of life perspectives differ based 
on the type of intervention received. Because the PedsQL IS assessment used in this 
study has not been used in SMA populations previously, we recommend this study be 
repeated with a larger sample size to 1) determine if this is an appropriate quality of life 
assessment for children with SMA and 2) provide replication data to compare with the 
data we collected. We suggest this larger follow-up study be conducted in approximately 
five years to allow for more time between when onasemnogene abeparvovec-xioi was 
approved by the FDA and data collection. Also, as SMA is considered a progressive 
disease, tracking how parent perspectives of their children’s quality of life changes over 
time with the various treatments available may be informative. Finally, as more 
individuals are diagnosed and treated for SMA, it may be beneficial to investigate genetic 
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counselors’, genetic professionals’, and other health care providers’ comfortability 
discussing the treatments and quality of life information with parents.  
Conclusion 
The purpose of this study was to directly compare parents’ perspectives of the 
quality of life of their children with SMA who received supportive care, nusinersen, 
onasemnogene abeparvovec-xioi, or both nusinersen and onasemnogene abeparvovec-
xioi. While the quality of life of children with SMA has been investigated previously, 
there is no apparent literature published that directly compares parents’ perspectives of 
the quality of life of their children with SMA who have received these interventions. We 
predicted that parents of children with SMA who received or are currently receiving 
treatment with nusinersen and/or onasemnogene abeparvovec-xioi would score their 
children’s quality of life higher than parents whose children received or are currently 
receiving only supportive care. Considering the present data, it was not possible to 
identify and associate a single treatment with conferring a statistically higher quality of 
life; however, the quantitative and qualitative responses collected allowed for an 
inference that parents believe their children with SMA have a greater quality of life when 
provided treatment over having only supportive care. Before the FDA approval of 
nusinersen and onasemnogene abeparvovec-xioi, genetic counselors, genetic 
professionals, and other healthcare providers who shared the diagnosis of SMA with 
parents had to also share that there was no known effective treatment. However, today 
when families hear the diagnosis of SMA, they can be hopeful for their child and family’s 
future because of the treatments available and the proven increase in quality of life with 
these treatments. Knowing how quality of life perspectives differ based on the type of 
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treatment received can help in the education of parents who are found to be carriers for 
SMA and are at risk of having an affected child, or who have a child that has been 
diagnosed with SMA. 
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Table 2.1 Surveys Available for Participants to Take in the Present Study 
The survey each participant took was dependent on if their child was living or deceased 
and the current age of their child or the child’s age at death. 
 
Survey 
Child with SMA 
Living or Deceased 
Current Age of Child 
or Age at Death 
Instrument(s) 
(CPAs) 
D Living 1-12 Months PedsQL IS 
E Deceased 1-12 Months PedsQL IS 
F Living 13-24 Months PedsQL IS 
G Deceased 13-24 Months PedsQL IS 
H Living 2-4 Years 
PedsQL GCS 
PedsQL NMM 
I Deceased 2-4 Years 
PedsQL GCS 
PedsQL NMM 
J Living Older than 4 Years None 






Figure 2.1 Participant Recruitment Social Media Image 







Figure 2.2 Survey Exclusion Process 
Out of 333 total survey responses, 231 met the inclusion criteria and were included in the final data analysis.   
             
333 Total Survey 
Responses 
299 Participants were the 
parent of a child with SMA
2 Participants declined to answer if their child 
was living or deceased
Excluded
2 Participants did not complete the appropriate 
survey for their child's age
Excluded
6 Participants did not complete greater than 50% 
of the quality of life assessment questions
Excluded
58 Participants did not provide informed consent 
by completing the survey
Excluded
231 Survey responses included in the final data 
analysis
34 Participants were not the 





Figure 2.3 Interventions Received by Children with SMA Aged 1-12 Months 
In total, 43 of the 231 surveys included in the final data analysis regarded children who 
















Figure 2.4 Interventions Received by Children with SMA Aged 13-24 Months 
In total, 39 of the 231 surveys included in the final data analysis regarded children who 















Figure 2.5 Interventions Received by Children with SMA Aged 2-4 Years 
In total, 28 of the 231 surveys included in the final data analysis regarded children who 













Figure 2.6 Interventions Received by Children with SMA Aged >4 years  
In total, 121 of the 231 surveys included in the final data analysis regarded children who 











Figure 2.7 Average Physical Summary Scores Regarding Children with SMA Aged 
1-12 Months  
The average physical quality of life summary score increased for children treated with 
both nusinersen and onasemnogene abeparvovec-xioi and those treated with 
onasemnogene abeparvovec-xioi only compared to children treated with nusinersen only 









































Figure 2.8 Average Psychosocial Summary Scores Regarding Children with SMA 
Aged 1-12 Months  
The average psychosocial quality of life summary score increased for children treated 
with nusinersen only compared to those treated with onasemnogene abeparvovec-xioi 












































Figure 2.9 Average Physical Summary Scores Regarding Children with SMA Aged 
13-24 Months  
The differences between the average physical quality of life summary scores for children 
treated with nusinersen only, onasemnogene abeparvovec-xioi only, both nusinersen and 









































Figure 2.10 Average Psychosocial Summary Scores Regarding Children with SMA 
Aged 13-24 Months  
The differences between the average psychosocial quality of life summary scores for 
children treated with nusinersen only, onasemnogene abeparvovec-xioi only, both 













































The purpose of this study was to directly compare parents’ perspectives of the 
quality of life of their children with SMA who received supportive care, nusinersen, 
onasemnogene abeparvovec-xioi, or both nusinersen and onasemnogene abeparvovec-
xioi. While the quality of life of children with SMA has been investigated previously, 
there is no apparent literature published that directly compares parents’ perspectives of 
the quality of life of their children with SMA who have received these interventions. We 
predicted that parents of children with SMA who received or are currently receiving 
treatment with nusinersen and/or onasemnogene abeparvovec-xioi would score their 
children’s quality of life higher than parents whose children received or are currently 
receiving only supportive care. Considering the present data, it was not possible to 
identify and associate a single treatment with conferring a statistically higher quality of 
life; however, the quantitative and qualitative responses collected allowed for an 
inference that parents believe their children with SMA have a greater quality of life when 
provided treatment over having only supportive care. Before the FDA approval of 
nusinersen and onasemnogene abeparvovec-xioi, genetic counselors, genetic 
professionals, and other healthcare providers who shared the diagnosis of SMA with 
parents had to also share that there was no known effective treatment. However, today 
when families hear the diagnosis of SMA, they can be hopeful for their child and family’s 
future because of the treatments available and the proven increase in quality of life with 
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these treatments. Knowing how quality of life perspectives differ based on the type of 
treatment received can help in the education of parents who are found to be carriers for 
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PARTICIPANT RECRUITMENT SOCIAL MEDIA TEXT
Calling all SMA parents! We need your help with a new research study. This 
research could help inform doctors, genetic counselors, and other medical professionals 
about our children and their quality of life. With treatments such as Spinraza and gene 
therapy/Zolgensma, it’s important that the medical community knows about our 
children's lives so that they can speak knowledgeably to parents facing a new diagnosis. 
This study is being done by Analyssa Tallas, a graduate student in the genetic counseling 
program at the University of South Carolina, who was inspired to go into this field 
because of Gwendolyn's SMA diagnosis. She is passionate about making a difference and 
has been an advocate for the SMA community for years. If you are the parent of a child 
with SMA, both living or deceased, treatment or no treatment or a combination of 
treatments, we hope you will participate. The survey will take approximately 15 minutes, 
and if you participate you will be entered to win a $50 Amazon gift card and a t-shirt 
from our NEVER GIVE UP. Shop! The link posted below will take you directly to 





PARTICIPANT RECRUITMENT LETTER 
Dear Potential Participant,  
You are invited to participate in a graduate research study focusing on parents’ 
perspectives of the quality of life of children with Spinal Muscular Atrophy (SMA). I am 
a graduate student in the genetic counseling program at the University of South Carolina 
School of Medicine. My research investigates parents’ perspectives of the quality of life 
of children with SMA. This research could help inform medical professionals so that they 
might be able to speak knowledgably about the parents’ perspectives of their child’s life. 
You are eligible to participate in this study if you are the parent of a child with SMA. 
You must be over 18 years of age and be able to read and write in English.  
Your participation in this study is voluntary. By completing this survey, you are 
consenting that you have read and understand this information. At any time, you may 
withdraw from the study by not completing the survey. All responses gathered will be 
kept anonymous and confidential. The results of this study might be published or 
presented at academic meetings; however, participants will not be identified. 
This survey should take approximately 15 minutes to complete. Participants who 
complete the survey will have the option to enter into a raffle for a $50 amazon gift card 
and a t-shirt from The Gwendolyn Strong Foundation. If you win, your prize will be sent 
to you at a later date, after all data has been collected. The email you provide in order to 
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enter the raffle will not be used for any other purposes beyond to send you the raffle prize 
if you have won. 
Thank you for your time and consideration to participate in this study. If you have 
any questions regarding this research, you may contact me directly using the contact 
information below. If you have any questions about your rights as a research participant, 
you may contact the Office of Research Compliance at the University of South Carolina 
at (803) 777-7095.  
Sincerely,  
Analyssa Tallas 





SURVEY FOR PARENTS WHOSE CHLD IS LIVING AND 1-12 MONTHS IN AGE 
Are you the parent of a child with SMA?   




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased?    
My child is living  
My child is deceased  
How old is your child? If your child is 24 months, please choose 13-24 months. If your 
child is older than 24 months but still 2, please choose the 2-4 option.  
1-12 months 
13-24 months  
2-4 years  
My child is older than 4 years 
How many copies of the SMN2 gene does your child have? _______ 
Please select the treatments(s) your child has received.  
 Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 




The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide. 
To confirm that you have completed the correct questionnaire, please enter your child’s 
age.____ 
If you have additional information you would like us to know about your child, his/her 
treatment(s), quality of life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below.  





SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT 1-12 MONTHS OF 
AGE 
Are you the parent of a child with SMA?   




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased?    
My child is living  
My child is deceased  
How old was your child when he/she passed away? If your child was 24 months, please 
choose 13-24 months. If your child was older than 24 months but still 2, please choose 
the 2-4 option.  
1-12 months  
13-24 months  
2-4 years  
My child was older than 4 years 
How many copies of the SMN2 gene did your child have? _______ 
Please select the treatments(s) your child received.  
 Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 
If your child did not receive either of these treatments, please select “none of the above”. 
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The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide. 
To confirm that you have completed the correct questionnaire, please enter how old your 
child was when he/she passed away. ____ 
If you have additional information you would like us to know about your child, his/her 
treatment(s), quality of life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below.  





SURVEY FOR PARENTS WHOSE CHILD IS LIVING AND 13-24 MONTHS IN AGE 
Are you the parent of a child with SMA?    




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased? 
My child is living 
My child is deceased  
How old is your child? If your child is 24 months, please choose 13-24 months. If your 
child is older than 24 months but still 2, please choose the 2-4 option.  
1-12 months 
13-24 months 
2-4 years  
My child is older than 4 years 
How many copies of the SMN2 gene does your child have? _______ 
Please select the treatments(s) your child has received.  
Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 




The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide. 
To confirm that you have completed the correct questionnaire, please enter your child’s 
age. ____ 
If you have additional information you would like us to know about your child, his/her 
treatment(s), quality of life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below.  





SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT 13-24 MONTHS OF 
AGE 
Are you the parent of a child with SMA?  




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased? 
My child is living 
My child is deceased  
How old was your child when he/she passed away? If your child was 24 months, please 
choose 13-24 months. If your child was older than 24 months but still 2, please choose 




My child was older than 4 years 
How many copies of the SMN2 gene did your child have? _______ 
Please select the treatments(s) your child received.  
 Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 
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If your child did not receive either of these treatments, please select “none of the above”. 
The PedsQL IS assessment was utilized in this survey. Permission granted by eProvide. 
To confirm that you have completed the correct questionnaire, please enter how old your 
child was when he/she passed away. ____ 
If you have additional information you would like us to know about your child, his/her 
treatment(s), quality of life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below.  





SURVEY FOR PARENTS WHOSE CHILD IS LIVING AND 2-4 YEARS IN AGE 
Are you the parent of a child with SMA?  




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased? 
My child is living  
My child is deceased  
How old is your child? If your child is 24 months, please choose 13-24 months. If your 




My child is older than 4 years 
How many copies of the SMN2 gene does your child have? _______ 
Please select the treatments(s) your child has received.  
Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 




The PedsQL GCS and PedsQL NMM assessments were utilized in this survey. 
Permission granted by eProvide. 
To confirm that you have completed the correct questionnaire, please enter your child’s 
age. ____ 
If you have additional information you would like us to know about your child, his/her 
treatment(s), quality of life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below. 





SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT 2-4 YEARS OF AGE 
Are you the parent of a child with SMA?  




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased? 
My child is living  
My child is deceased  
How old was your child when he/she passed away? If your child was 24 months, please 
choose 13-24 months. If your child was older than 24 months but still 2, please choose 




My child was older than 4 years 
How many copies of the SMN2 gene did your child have? _______ 
Please select the treatments(s) your child received.  
 Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 
If your child did not receive either of these treatments, please select “none of the above”. 
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The PedsQL GCS and PedsQL NMM assessments were utilized in this survey. 
Permission granted by eProvide. 
To confirm that you have completed the correct questionnaire, please enter how old your 
child was when he/she passed away. ____ 
If you have additional information you would like us to know about your child, his/her 
treatment(s), quality of life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below.  





SURVEY FOR PARENTS WHOSE CHILD IS LIVING AND OLDER THAN 4 
YEARS OF AGE 
Are you the parent of a child with SMA?  




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased? 
My child is living  
My child is deceased  
How old is your child? If your child is 24 months, please choose 13-24 months. If your 




My child is older than 4 years 
How many copies of the SMN2 gene does your child have? _______ 
Please select the treatments(s) your child has received.  
Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 
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If your child has not received either of these treatments, please select “none of the 
above”. 
If you would like to share information about your child, his/her treatment(s), quality of 
life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below.  





SURVEY FOR PARENTS WHOSE CHILD IS DECEASED AT OLDER THAN 4 
YEARS OF AGE 
Are you the parent of a child with SMA?  




We would like to provide you with questions that use the appropriate tense; is your child 
with SMA living or deceased? 
My child is living  
My child is deceased  
How old was your child when he/she passed away? If your child was 24 months, please 
choose 13-24 months. If your child was older than 24 months but still 2, please choose 




My child was older than 4 years 
How many copies of the SMN2 gene did your child have? _______ 
Please select the treatments(s) your child received.  
 Spinraza (nusinersen) 
 Zolgensma (onasemnogene abeparvovec-xioi) 
 None of the above 
If your child did not receive either of these treatments, please select “none of the above”. 
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If you would like to share information about your child, his/her treatment(s), quality of 
life, etc. please use the space provided below. _______ 
As a token of our appreciation for taking this survey, we will have a raffle for a $50 
amazon gift card and a t-shirt from The Gwendolyn Strong Foundation. 
If you are interested in entering the raffle, please enter your email below.  
By providing your email you acknowledge that your answers to this survey may not be 
anonymous.  _____________________________. 
